64 results
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
progression with a higher score indicating a greater level of disability. FXN Level* (% of Normal Level) Age of Onset (Years) FARS** (Change/Year) 11.2 7
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
with a higher score indicating a greater level of disability. FXN Level* (% of Normal Level) Age of Onset (Years) FARS** (Change/Year) 11.2 7 2.9 22.0 11 2.1 … score indicating a greater level of disability. **FXN levels measured in peripheral blood mononuclear cells (PBMCs). FXN levels as measured
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
employees, including our named executive officers, including health, dental, life, vision and disability insurance.
We do not maintain any defined
8-K
EX-99.2
mssfi
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
yar vczmft81v
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
03n5156u75wrnu7q
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
petaf i5hlwz
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
smr3qp3le7
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.3
la5iquy8u
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
sc7hweja s6bm9r
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
205h 59mdutdt
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
hv2g7 wy2df
14 Aug 23
Other Events
8:00am
8-K
EX-1.1
n3m z0nvx5
14 Sep 22
Entry into a Material Definitive Agreement
9:01am